Cover
Title
Copyright
Contents
Contributors
Preface
Abbreviations
Part I: Introduction and Overview
Chapter 1: Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses
Normal Hematopoiesis
Cytopenias
Cytoses
Conclusion
References for Supplemental Reading
Chapter 2: Familial/Inherited Mutations and Risks of Hematologic Malignancies
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
References
Chapter 3: Diagnostic Approaches to Hematologic Malignancies
Introduction
Morphology
Flow Cytometry
Immunohistochemical Staining
Polymerase Chain Reaction
Cytogenetics
Fluorescence In-Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism Arrays
Next-Generation Sequencing
Conclusion
References for Supplemental Reading
References
Chapter 4: Minimal Residual Disease Assays
Introduction
Methods
MRD Testing in Acute Myeloid Leukemia
MRD Testing with Acute Lymphoblastic Leukemia
MRD Testing with Multiple Myeloma
References for Supplemental Reading
Part II: Myeloproliferative Neoplasms
Chapter 5: Polycythemia Vera
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Genomics and Personalized Medicine
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 6: Essential Thrombocythemia
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 7: Primary Myelofibrosis
Introduction
Diagnosis
Key Management Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 8: Chronic Myelogenous Leukemia
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Monitoring Response to TKI Therapy
Treatment-Free Remission
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 9: Chronic Neutrophilic Leukemia
Introduction
Diagnosis
Key Diagnostic Dilemma
Diagnostic Advances
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 10: Systemic Mastocytosis
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 11: PDGFRA/PDGFRB/FGFR1 Myeloid Neoplasms
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Trials
References for Supplemental Reading
Part III: Myelodysplastic and Bone Marrow Failure Syndromes
Chapter 12 Myelodysplastic Syndromes
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 13: Aplastic Anemia
Introduction
Pathogenesis
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 14: Paroxysmal Nocturnal Hemoglobinuria
Introduction
Pathogenesis
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part IV: Myelodysplastic/Myeloproliferative Neoplasms
Chapter 15: Myelodysplastic/Myeloproliferative Overlap Syndromes
Introduction
Diagnosis
Juvenile Myelomoncytic Leukemia (JMML)
Atypical Chronic Myeloid Leukemia
MDS/MPN-Unclassified
MDS/MPN-RS-T
References for Supplemental Reading
Chapter 16: Chronic Myelomonocytic Leukemia
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part V: Acute Myeloid Leukemia and Related Syndromes
Chapter 17: Acute Myeloid Leukemia
Introduction
Diagnosis
Prognosis
Treatment
Treatment in Patients Eligible for Induction Chemotherapy
Treatment in Patients Ineligible for Induction Chemotherapy
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 18: Secondary AML and AML-MRC
Introduction
Diagnosis
Pathogenesis
Risk Stratification
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 19: Acute Promyelocytic Leukemia
Introduction
Diagnosis
Variant Forms
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 20: Blastic Plasmacytoid Dendritic Cell Neoplasm
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part VI: Acute Lymphoid Leukemia
Chapter 21: B-Lymphoblastic Leukemia/Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 22: BCR-ABL1+ B-Lymphoblastic Leukemia
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 23: T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part VII: Acute Leukemia of Ambiguous Lineage
Chapter 24: Acute Leukemia of Ambiguous Lineage
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part VIII: Mature T- and NK-Cell Leukemia
Chapter 25: T-Cell Prolymphocytic Leukemia
Introduction
Diagnosis
Genetics
Key Differential Diagnoses
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 26: T-Cell Large Granular Lymphocytic Leukemia
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 27: Aggressive Natural Killer Cell Leukemia
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part IX: Plasma Cell Disorders
Chapter 28: Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas
Introduction
Monoclonal Gammopathy of Unknown Significance
Diagnosis
Prognosis
Surveillance
Smoldering Myeloma
Diagnosis
Prognosis and Risk Stratification
Treatment
Surveillance
Plasmacytoma
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 29: Multiple Myeloma
Introduction
Evaluation
Diagnosis
Key Diagnostic Dilemma
Prognosis
Monitoring
Treatment
Future Therapies
References for Supplemental Reading
Chapter 30: WaldenstrΓΆm Macroglobulinemia
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 31: Immunoglobulin Light Chain Amyloidosis
Introduction
Diagnosis
Staging and Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part X: Hodgkin Lymphoma
Chapter 32: Hodgkin Lymphoma
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part XI: Non-Hodgkin Lymphoma
Chapter 33: Diagnosis and Classification of Non-Hodgkin Lymphomas
Introduction
Summary
References
Part XII: Mature B-Cell Lymphoma: Very Aggressive
Chapter 34: Burkitt Lymphoma
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part XII: Mature B-Cell Lymphoma: Aggressive
Chapter 35: Diffuse Large B-Cell Lymphoma
Introduction
Diagnosis
Staging
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 36: Double-Hit Lymphoma
Introduction
Genetic Basis
Diagnostic Differentiation from Double Expressors
Treatment and Outcomes
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 37: Mantle Cell Lymphoma
Introduction
Pathogenesis
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trial
References for Supplemental Reading
Chapter 38: Primary Mediastinal Large B-Cell Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 39: Primary Central Nervous System Lymphoma
Introduction
Diagnosis and Initial Evaluation
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 40: HIV-Related Lymphomas
Introduction
Diagnosis
Prognosis
Treatment
References for Supplemental Reading
Part XII: Mature B-Cell Lymphoma: Indolent
Chapter 41: Follicular Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Training Clinical Trials
References for Supplemental Reading
Chapter 42: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 43: Hairy Cell Leukemia
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 44: Marginal Zone Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Surveillance
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 45: Mucosa-Associated Lymphoid Tissue Lymphoma
Introduction
Diagnosis
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part XIII: Mature T- and NK-Cell Lymphoma
Chapter 46: Adult T-Cell Leukemia/Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Classification
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 47: Anaplastic Large Cell Lymphoma
Introduction
Clinical Features/Presentation
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 48: Extranodal Natural Killer/T-Cell Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 49: Mycosis Fungoides
Introduction
Diagnosis
Key Diagnostic Dilemma
Staging
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 50: Hepatosplenic T-Cell Lymphoma
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
References for Supplemental Reading
Part XIV: Histiocytic/Dendritic Cell Neoplasms
Chapter 51: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Histiocytic Sarco
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 52: Hemophagocytic Lymphohistiocytosis
Introduction
Diagnosis
Key Diagnostic Dilemma
Prognosis
Treatment
Relapse/Refractory Disease
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part XV: Bone Marrow Transplantation
Chapter 53: Autologous Hematopoietic Cell Transplantation
Introduction
Pre-Transplant Workup
Stem Cell Processing
Engraftment
Transplant Complications
Post-Transplant Care
References for Supplemental Reading
Chapter 54: Allogeneic Hematopoietic Cell Transplantation
Introduction
Pre-Transplant Workup
Donor Selection
Conditioning Regimens
Graft-Versus-Host Disease
Infection
Other Toxicities/Complications
References for Supplemental Reading
Part XVI: New Cellular Immunotherapy
Chapter 55: Car-T Overview and Novel Cellular Therapeutic Options, Including TCR Gene Transfers
Introduction
Chimeric Antigen Receptor (CAR)
TCR Therapy
Future Directions
References for Supplemental Reading
Chapter 56: CD19 Car T-Cell Therapy
Introduction
Tisagenlecleucel
Axicabtagene Ciloleucel
Lisocabtagene Maraleucel
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 57: Cytokine Release Syndrome and Other Toxicities Associated with Novel Cellular Therapies
Introduction
Diagnosis: Cytokine Release Syndrome
Diagnosis: Neurologic Toxicity
Hematologic Toxicities
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Part XVII: Emergencies in Hematology
Chapter 58: Cancer-Associated Thrombosis in Hematologic Malignancies
Introduction
Epidemiology
Prevention and Treatment
Special Populations
Prognosis
Potential Practice-Changing Clinical Trials
References for Supplemental Reading
Chapter 59: Tumor Lysis Syndrome
Introduction
Pathophysiology
Diagnosis
Population at Risk
Prevention
Treatment
References for Supplemental Reading
Chapter 60: Thrombotic Microangiopathy
Introduction
Primary TMA Syndromes
Secondary TMA
Diagnostic Evaluation
Treatment
References for Supplemental Reading
Chapter 61: Therapeutic Apheresis Indications
Introduction
Therapeutic Apheresis Indications in Hematologic Malignancies
Practical Considerations
Adverse Effects
References for Supplemental Reading
Part XVIII: New Clinical Cases in Malignant Hematology
Chapter 62: Challenging Case Vignettes with Follow-Up Questions
Introduction
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8
Case 9
Case 10
Appendix: Pathology Supplement
References
Index